|
CA1327358C
(en)
|
1987-11-17 |
1994-03-01 |
Morio Fujiu |
Fluoro cytidine derivatives
|
|
JP3040121B2
(ja)
|
1988-01-12 |
2000-05-08 |
ジェネンテク，インコーポレイテッド |
増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
|
|
US6407213B1
(en)
|
1991-06-14 |
2002-06-18 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
|
TW254946B
(lt)
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
|
PL181304B1
(pl)
|
1994-07-22 |
2001-07-31 |
Lilly Co Eli |
Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
|
|
US5476932A
(en)
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
DE69622183D1
(de)
|
1995-11-07 |
2002-08-08 |
Kirin Brewery |
Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
US6002008A
(en)
|
1997-04-03 |
1999-12-14 |
American Cyanamid Company |
Substituted 3-cyano quinolines
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
US6251912B1
(en)
|
1997-08-01 |
2001-06-26 |
American Cyanamid Company |
Substituted quinazoline derivatives
|
|
US6288082B1
(en)
|
1998-09-29 |
2001-09-11 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
US6297258B1
(en)
|
1998-09-29 |
2001-10-02 |
American Cyanamid Company |
Substituted 3-cyanoquinolines
|
|
DE69913364T2
(de)
|
1998-09-29 |
2004-06-09 |
Wyeth Holdings Corp. |
Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
|
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
|
WO2001051919A2
(en)
|
2000-01-07 |
2001-07-19 |
Transform Pharmaceuticals, Inc. |
High-throughput formation, identification, and analysis of diverse solid-forms
|
|
US6384051B1
(en)
|
2000-03-13 |
2002-05-07 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
MXPA03001245A
(es)
|
2000-08-11 |
2003-05-27 |
Wyeth Corp |
Metodo para el tratamiento del carcionma positivo para receptores de estrogeno.
|
|
TWI286074B
(en)
|
2000-11-15 |
2007-09-01 |
Wyeth Corp |
Pharmaceutical composition containing CCI-779 as an antineoplastic agent
|
|
TWI296196B
(en)
|
2001-04-06 |
2008-05-01 |
Wyeth Corp |
Antineoplastic combinations
|
|
CA2442849A1
(en)
|
2001-04-06 |
2002-10-17 |
Wyeth |
Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
|
|
TWI233359B
(en)
|
2001-04-06 |
2005-06-01 |
Wyeth Corp |
Pharmaceutical composition for treating neoplasm
|
|
CN100496485C
(zh)
|
2001-06-01 |
2009-06-10 |
惠氏公司 |
抗肿瘤组合
|
|
ZA200603888B
(en)
|
2001-06-01 |
2007-05-30 |
Wyeth Corp |
Antineoplastic combinations
|
|
UA77200C2
(en)
|
2001-08-07 |
2006-11-15 |
Wyeth Corp |
Antineoplastic combination of cci-779 and bkb-569
|
|
WO2003050090A1
(en)
|
2001-11-27 |
2003-06-19 |
Wyeth Holdings Corporation |
3-cyanoquinolines as inhibitors of egf-r and her2 kinases
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
US7384940B2
(en)
|
2002-06-05 |
2008-06-10 |
Cedars-Sinai Medical Center |
Method of treating cancer using kinase inhibitors
|
|
WO2004004644A2
(en)
|
2002-07-05 |
2004-01-15 |
Beth Israel Deaconess Medical Center |
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
|
|
US20040209930A1
(en)
|
2002-10-02 |
2004-10-21 |
Carboni Joan M. |
Synergistic methods and compositions for treating cancer
|
|
CL2004000016A1
(es)
|
2003-01-21 |
2005-04-15 |
Wyeth Corp |
Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
|
|
UA83484C2
(uk)
|
2003-03-05 |
2008-07-25 |
Уайт |
Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
|
|
CN1777424A
(zh)
|
2003-04-22 |
2006-05-24 |
惠氏公司 |
抗肿瘤联合药物
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
US8637553B2
(en)
|
2003-07-23 |
2014-01-28 |
Bayer Healthcare Llc |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
US20050025825A1
(en)
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
|
JP2007501238A
(ja)
|
2003-08-01 |
2007-01-25 |
ワイス・ホールディングズ・コーポレイション |
癌の治療および阻害のための上皮増殖因子受容体キナーゼ阻害剤と細胞障害性物質との組み合わせの使用
|
|
EP1660453A2
(en)
|
2003-08-19 |
2006-05-31 |
Wyeth Holdings Corporation |
Process for the preparation of 4-amino-3-quinolinecarbonitriles
|
|
BR0318503A
(pt)
|
2003-09-15 |
2006-09-12 |
Wyeth Corp |
quinolinas substituìdas como inibidores de enzima proteìna tirosina cinase
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
|
EP1756137A4
(en)
|
2003-11-05 |
2007-10-31 |
Univ Texas |
DIAGNOSTIC AND THERAPEUTIC PROCEDURES AND COMPOSITIONS CONCERNING PTEN AND BREAST CANCER
|
|
PE20050928A1
(es)
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
|
AR047988A1
(es)
|
2004-03-11 |
2006-03-15 |
Wyeth Corp |
Combinaciones antineoplásicas de cci-779 y rituximab
|
|
SI1733056T1
(sl)
|
2004-03-31 |
2013-10-30 |
The General Hospital Corporation |
Postopek določanja odzivnosti rakaste tvorbe na zdravljenje, kjer je tarča receptor epidermalnega rastnega faktorja
|
|
BRPI0513589A
(pt)
|
2004-07-23 |
2008-05-13 |
Astrazeneca Ab |
método para selecionar um mamìfero tendo ou suspeito de ter um tumor para tratamento com uma droga de receptor de erbb
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
TW200616612A
(en)
|
2004-10-08 |
2006-06-01 |
Wyeth Corp |
Method for the teatment of polycystic kidney disease field of invention
|
|
CN101039952A
(zh)
|
2004-10-13 |
2007-09-19 |
惠氏公司 |
作为pi3k抑制剂的17－羟基渥曼青霉素类似物
|
|
US20080254497A1
(en)
|
2004-10-15 |
2008-10-16 |
Monogram Biosciences, Inc. |
Response Predictors for Erbb Pathway-Specific Drugs
|
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
|
NZ556673A
(en)
|
2005-02-03 |
2010-03-26 |
Gen Hospital Corp |
Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
|
|
WO2006081985A1
(en)
|
2005-02-04 |
2006-08-10 |
F. Hoffmann-La Roche Ag |
Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
|
|
AU2006217692A1
(en)
|
2005-02-28 |
2006-08-31 |
Eisai R & D Management Co., Ltd. |
Novel combinational use of sulfonamide compound
|
|
CA2599445C
(en)
|
2005-03-09 |
2022-05-03 |
Abbott Laboratories |
Diagnostics method for identifying candidate patients for the treatment with trastuzumab
|
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
|
EP1871371A2
(en)
|
2005-04-14 |
2008-01-02 |
Wyeth |
Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
|
|
US20110045459A1
(en)
|
2005-04-21 |
2011-02-24 |
Mischel Paul S |
Molecular determinants of EGFR kinase inhibitor response in glioblastoma
|
|
CA2603806C
(en)
|
2005-04-28 |
2013-03-19 |
Wyeth |
Micronized tanaproget, compositions, and methods of preparing the same
|
|
CA2603445A1
(en)
|
2005-05-12 |
2006-11-16 |
Pfizer Inc. |
Anticancer combination therapy using sunitinib malate
|
|
KR20080016600A
(ko)
|
2005-05-25 |
2008-02-21 |
와이어쓰 |
3-시아노-퀴놀린의 제조 방법 및 이에 의해 제조된 중간생성물
|
|
AU2006249600A1
(en)
|
2005-05-25 |
2006-11-30 |
Wyeth |
Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
|
|
DE102005053679A1
(de)
|
2005-06-24 |
2006-12-28 |
Bayer Healthcare Ag |
Therapeutischer Einsatz von Moxifloxacin zur Rekonstruktion von Funktionsstörungen des Immunsystems
|
|
PE20070192A1
(es)
|
2005-07-15 |
2007-03-16 |
Wyeth Corp |
Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
|
|
WO2007015569A1
(ja)
|
2005-08-01 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を予測する方法
|
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
|
ZA200802854B
(en)
|
2005-10-05 |
2009-06-24 |
Astrazeneca Ltd |
Method to predict or monitor the response of a patient to an ErbB receptor drug
|
|
WO2007050495A2
(en)
|
2005-10-26 |
2007-05-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
|
KR101354828B1
(ko)
|
2005-11-04 |
2014-02-18 |
와이어쓰 엘엘씨 |
ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
|
|
AR058505A1
(es)
|
2005-11-04 |
2008-02-06 |
Wyeth Corp |
Combinaciones antineoplasicas de temsirolimus y malato de sunitinib
|
|
CA2629249C
(en)
|
2005-11-11 |
2015-05-05 |
Boehringer Ingelheim International Gmbh |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
|
ES2335308T3
(es)
|
2005-11-24 |
2010-03-24 |
AICURIS GMBH & CO. KG |
Parapoxvirus en combinacion con agentes quimioterapeuticos clasicos como bioquimoteparia para el tratamiento del cancer.
|
|
WO2007075794A2
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Oral formulations comprising tigecycline
|
|
WO2007095038A2
(en)
|
2006-02-09 |
2007-08-23 |
Novartis Ag |
Mutations and polymorphisms of erbb2
|
|
TW200806282A
(en)
|
2006-05-05 |
2008-02-01 |
Wyeth Corp |
Solid dosage formulations
|
|
WO2007137187A2
(en)
|
2006-05-18 |
2007-11-29 |
Molecular Profiling Institute, Inc. |
System and method for determining individualized medical intervention for a disease state
|
|
US20100113299A1
(en)
|
2008-10-14 |
2010-05-06 |
Von Hoff Daniel D |
Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
|
|
TW200808728A
(en)
|
2006-05-23 |
2008-02-16 |
Wyeth Corp |
Method of preparing 4-halogenated quinoline intermediates
|
|
JP5399900B2
(ja)
|
2006-06-30 |
2014-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ｉｇｆｂｐ２インヒビター
|
|
WO2008034776A1
(en)
|
2006-09-18 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Method for treating cancer harboring egfr mutations
|
|
JP2010504974A
(ja)
|
2006-09-28 |
2010-02-18 |
フォリカ，インコーポレーテッド |
新しい毛嚢を生成させ毛髪を成長させる方法、キット、及び組成物
|
|
EP2073823A1
(en)
|
2006-10-13 |
2009-07-01 |
Medigene AG |
Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
|
|
AU2007334456A1
(en)
|
2006-12-13 |
2008-06-26 |
Merck Sharp & Dohme Corp. |
Methods of cancer treatment with IGF1R inhibitors
|
|
WO2008076257A2
(en)
|
2006-12-13 |
2008-06-26 |
Schering Corporation |
Treating cancer with anti-igflr antibody 19d12 = sch 717454
|
|
EP2124951B1
(en)
|
2006-12-21 |
2014-05-21 |
Vertex Pharmaceuticals Inc. |
5-cyan0-4- (pyrrolo[2, 3b]pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
|
|
WO2008089087A2
(en)
|
2007-01-12 |
2008-07-24 |
Wyeth |
Tablet-in-tablet compositions
|
|
CN104043123B
(zh)
|
2007-01-25 |
2019-08-13 |
达娜-法勃肿瘤研究所公司 |
抗egfr抗体在治疗egfr突变体介导的疾病中的用途
|
|
TW200836774A
(en)
|
2007-02-01 |
2008-09-16 |
Takeda Pharmaceutical |
Solid preparation
|
|
WO2008121467A2
(en)
|
2007-02-28 |
2008-10-09 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for treating cancer
|
|
GB0706633D0
(en)
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
|
CA2683559C
(en)
|
2007-04-13 |
2019-09-24 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
|
WO2008130910A1
(en)
|
2007-04-19 |
2008-10-30 |
Wellstat Biologics Corporation |
Detection her-2/neu protein from non-isolated circulating cancer cells and treatment
|
|
WO2008136838A1
(en)
|
2007-05-04 |
2008-11-13 |
Trustees Of Dartmouth College |
Novel amide derivatives of cddo and methods of use thereof
|
|
WO2009005673A1
(en)
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Anti-igf1r
|
|
CN104586832B
(zh)
|
2007-09-10 |
2018-02-16 |
北京强新生物科技有限公司 |
用于癌症治疗的组合物和方法
|
|
EP2205076A4
(en)
|
2007-09-24 |
2010-12-29 |
Tragara Pharmaceuticals Inc |
POLYTHERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DOUBLE INHIBITORS OF EGFR ÝERBB1 AND HER-2 ÝERBB2
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
WO2009055343A2
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
JP2011502571A
(ja)
|
2007-11-05 |
2011-01-27 |
ピュアテック ベンチャーズ |
医薬化合物を投与するための方法、キット、および組成物
|
|
WO2009079587A2
(en)
|
2007-12-18 |
2009-06-25 |
Schering Corporation |
Biomarkers for sensitivity to anti-igf1r therapy
|
|
US20100297118A1
(en)
|
2007-12-27 |
2010-11-25 |
Macdougall John |
Therapeutic Cancer Treatments
|
|
WO2009105234A2
(en)
|
2008-02-19 |
2009-08-27 |
Combinatorx, Incorporated |
Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein
|
|
ES2398618T3
(es)
|
2008-02-25 |
2013-03-20 |
Nestec S.A. |
Selección de fármacos para terapia del cáncer de mama utilizando matrices de anticuerpos
|
|
WO2009111073A2
(en)
|
2008-03-06 |
2009-09-11 |
Odyssey Thera, Inc. |
High-content and high throughput assays for identification of lipid-regulating pathways, and novel therapeutic agents for lipid disorders
|
|
US20110104256A1
(en)
|
2008-03-25 |
2011-05-05 |
Yaolin Wang |
Methods for treating or preventing colorectal cancer
|
|
EP2977468B1
(en)
|
2008-03-27 |
2019-06-19 |
Vascular Biosciences, Inc. |
Methods of novel therapeutic candidate identification through gene expression analysis in pulmonary arterial hypertension
|
|
US20090246198A1
(en)
|
2008-03-31 |
2009-10-01 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
WO2009126662A1
(en)
|
2008-04-08 |
2009-10-15 |
Syndax Pharmaceuticals, Inc. |
Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
|
|
HRP20182060T1
(hr)
|
2008-04-18 |
2019-03-22 |
Reata Pharmaceuticals, Inc. |
Antioksidantni modulatori upale: derivati oleanolne kiseline s amino i drugim modifikacijama na c-17
|
|
ES2613964T3
(es)
|
2008-04-18 |
2017-05-29 |
Reata Pharmaceuticals, Inc. |
Moduladores de inflamación antioxidantes: Derivados de ácido oleanólico homologado C-17
|
|
TW201004627A
(en)
|
2008-04-18 |
2010-02-01 |
Reata Pharmaceuticals Inc |
Antioxidant inflammation modulators: novel derivatives of oleanolic acid
|
|
EA020467B1
(ru)
|
2008-04-18 |
2014-11-28 |
Ритэ Фамэсутикл, Инк. |
Соединения, обладающие противовоспалительной активностью, и фармацевтическая композиция на их основе
|
|
KR101713140B1
(ko)
|
2008-04-18 |
2017-03-08 |
리타 파마슈티컬스 잉크. |
Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
|
|
US20110129456A1
(en)
|
2008-05-05 |
2011-06-02 |
Yaolin Wang |
Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
|
|
WO2009151910A2
(en)
|
2008-05-25 |
2009-12-17 |
Wyeth |
Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
|
|
ES2531322T3
(es)
|
2008-06-17 |
2015-03-13 |
Wyeth Llc |
Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
|
|
ES2449396T3
(es)
|
2008-07-22 |
2014-03-19 |
Trustees Of Dartmouth College |
Cianoenonas monocíclicas y métodos de uso de las mismas
|
|
CN102202667A
(zh)
|
2008-08-04 |
2011-09-28 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
|
WO2010030835A2
(en)
|
2008-09-11 |
2010-03-18 |
Wyeth Llc |
Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
|
|
WO2010048477A2
(en)
|
2008-10-24 |
2010-04-29 |
Wyeth Llc |
Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
|
|
WO2010054051A1
(en)
|
2008-11-07 |
2010-05-14 |
Santaris Pharma A/S |
Erbb-3 (her3)-selective combination therapy
|
|
WO2010085845A1
(en)
|
2009-01-28 |
2010-08-05 |
The University Of Queensland |
Cancer therapy and/or diagnosis
|
|
TW201032796A
(en)
|
2009-02-04 |
2010-09-16 |
Bipar Sciences Inc |
Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
|
|
WO2010098627A2
(ko)
|
2009-02-27 |
2010-09-02 |
한올바이오파마주식회사 |
약제학적 제제
|
|
CN105541836A
(zh)
|
2009-03-11 |
2016-05-04 |
奥克兰联合服务有限公司 |
激酶抑制剂的前药形式及其在治疗中的用途
|
|
KR20140036332A
(ko)
|
2009-04-06 |
2014-03-25 |
와이어쓰 엘엘씨 |
네라티닙을 이용한 유방암의 치료법
|
|
AR076053A1
(es)
|
2009-04-14 |
2011-05-18 |
Schering Corp |
Derivados de pirazolo[1,5-a]pirimidina como inhibidores de mtor
|
|
WO2010124009A2
(en)
|
2009-04-21 |
2010-10-28 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
ES2659725T3
(es)
|
2009-05-05 |
2018-03-19 |
Dana-Farber Cancer Institute, Inc. |
Inhibidores de EGFR y procedimiento de tratamiento de trastornos
|
|
AU2010266342A1
(en)
|
2009-07-02 |
2012-01-19 |
Wyeth Llc |
3-cyanoquinoline tablet formulations and uses thereof
|
|
WO2011008054A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
WO2011008053A2
(ko)
|
2009-07-17 |
2011-01-20 |
한올바이오파마주식회사 |
Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
|
|
WO2011025271A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
WO2011025267A2
(ko)
|
2009-08-25 |
2011-03-03 |
한올바이오파마주식회사 |
메트포르민 메탄설폰산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
KR101190953B1
(ko)
|
2009-08-25 |
2012-10-12 |
한올바이오파마주식회사 |
메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
|
|
EP2470212A4
(en)
|
2009-10-01 |
2013-12-04 |
Csl Ltd |
METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA
|
|
CN107308130B
(zh)
|
2009-11-09 |
2021-06-15 |
惠氏有限责任公司 |
包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
|
|
RS59599B2
(sr)
|
2009-11-09 |
2023-03-31 |
Wyeth Llc |
Formulacije tableta neratinib maleata
|
|
NO2719708T3
(lt)
|
2009-11-13 |
2018-03-24 |
|
|
|
US20130012465A1
(en)
|
2009-12-07 |
2013-01-10 |
Boehringer Ingelheim International Gmbh |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
|
EP3575413A1
(en)
|
2009-12-11 |
2019-12-04 |
Wyeth LLC |
Phosphatidylinositol-3-kinase pathway biomarkers
|
|
WO2011087926A1
(en)
|
2010-01-13 |
2011-07-21 |
Wyeth Llc |
A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR
|